{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fink SP"],"funding":["NCI NIH HHS"],"pagination":["291-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4322189"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(2)"],"pubmed_abstract":["Non-steroidal anti-inflammatory drugs prevent colorectal cancer by inhibiting cyclooxygenase (COX) enzymes that synthesize tumor-promoting prostaglandins. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a tumor suppressor that degrades tumor-promoting prostaglandins. Murine knockout of 15-PGDH increases susceptibility to azoxymethane-induced colon tumors. It also renders these mice resistant to celecoxib, a selective inhibitor of inducible COX-2 during colon neoplasia. Similarly, humans with low colonic 15-PGDH are also resistant to colon adenoma prevention with celecoxib. Here, we used aspirin and sulindac, which inhibit both COX-1 and COX-2, in order to determine if these broader COX inhibitors can prevent colon tumors in 15-PGDH knockout (KO) mice. Unlike celecoxib, sulindac proved h"],"journal":["Carcinogenesis"],"pubmed_title":["Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs."],"pmcid":["PMC4322189"],"funding_grant_id":["N01 CN-43302","P50 CA150964"],"pubmed_authors":["Dawson DM","Markowitz SD","Zhang Y","Yang P","Kresak A","Chen Y","Willis JE","Kopelovich L","Barnholtz-Sloan JS","Fink SP","Lawrence EG"],"additional_accession":[]},"is_claimable":false,"name":"Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.","description":"Non-steroidal anti-inflammatory drugs prevent colorectal cancer by inhibiting cyclooxygenase (COX) enzymes that synthesize tumor-promoting prostaglandins. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a tumor suppressor that degrades tumor-promoting prostaglandins. Murine knockout of 15-PGDH increases susceptibility to azoxymethane-induced colon tumors. It also renders these mice resistant to celecoxib, a selective inhibitor of inducible COX-2 during colon neoplasia. Similarly, humans with low colonic 15-PGDH are also resistant to colon adenoma prevention with celecoxib. Here, we used aspirin and sulindac, which inhibit both COX-1 and COX-2, in order to determine if these broader COX inhibitors can prevent colon tumors in 15-PGDH knockout (KO) mice. Unlike celecoxib, sulindac proved h","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Feb","modification":"2025-04-21T22:25:38.496Z","creation":"2019-03-27T01:44:54Z"},"accession":"S-EPMC4322189","cross_references":{"pubmed":["25503930"],"doi":["10.1093/carcin/bgu241"]}}